Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 13, 2018 01:15 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate injection) 40 mg/mL

--Glatopa 40 mg/mL is a fully substitutable, AP-rated generic version of three times-a-week COPAXONE® (glatiramer acetate injection) 40 mg/mL for the treatment of patients with relapsing forms of...
February 08, 2018 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Webcast Presentation at the LEERINK Partners 7th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
February 07, 2018 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
January 30, 2018 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer

-- McPherson, Kansas facility compliance status amended to Voluntary Action Indicated (VAI)-- -- VAI status provides the potential for the near-term FDA approval of Sandoz’s Glatopa 40 mg ANDA-- ...
January 05, 2018 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers

CAMBRIDGE, Mass., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
January 03, 2018 16:05 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)

CAMBRIDGE, Mass., HERTFORDSHIRE, United Kingdom and PITTSBURGH, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL) today announced...
December 28, 2017 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Webcast Presentation at the 36th Annual J. P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
November 08, 2017 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2017 Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
November 01, 2017 08:05 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

-- Ended third quarter with a strong cash position of $423M -- CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results...
November 01, 2017 08:00 ET | Source: Momenta Pharmaceuticals, Inc.; Mylan N.V.

Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)

CAMBRIDGE, Mass. and HERTFORDSHIRE, United Kingdom and PITTSBURGH, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right